T 2 relaxation times corresponded to cervix tissue at 1.5T and 3T. 1,2 MRI scans were performed on a 1.5T Ingenia and a 3T Achieva Philips system using 2D Spin Echo (SE) and 3D Spoiled Gradient Echo (SPGR) sequences. CT scans were acquired using our standard clinical protocol and were used as the gold standard for applicator reconstruction. Geometrical distortion was quantitatively assessed after non-deformable MR to CT image registration. Results: On both 1.5T and 3T the multiplanar T 2 -weighted SE scans provided good soft tissue contrast. However, on 3T, the T 2 -weighted SE scans showed detrimental distortion artifacts, making them unsuitable for accurate anatomical delineation and applicator reconstruction. On 1.5T, these artifacts were significantly reduced and the image quality was expected to be adequate for delineation. For applicator reconstruction a new 3D sequence with an extremely short TE was developed called '3D_applicator', based on the SPGR sequence by Petit et al. 3 The intrauterine and ovoid probes, as well as the needles were clearly visualized using this sequence ( Figure  1) . The total scan time of the MRI protocol, consisting of a survey scan, three multiplanar T 2 -weighted SE scans and the '3D_applicator' scan, was less than 17 minutes. The specific absorption rate (SAR) of all sequences was amply below the limits set by the applicator manufacturer. 
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Access to evidence-based radiotherapy in Europe 2020 ñ are we on the right track?
C. Grau 1 1 Aarhus University Hospital, Oncology, Aarhus C, Denmark
Radiotherapy is an important modality in the multidisciplinary approach towards cancer; and it is the vision of ESTRO for the 2020 horizon that "Every cancer patient in Europe will have access to state-of-the-art radiation therapy, as part of a multidisciplinary approach where treatment is individualized for the specific patient's cancer, taking account of the patient's personal circumstances" But how many patients should receive radiotherapy, and what is the current access to state-of-theart radiotherapy resources in the European countries? And how will these parameters evolve towards 2020? These topics are currently addressed in the ESTRO Health Economics in Radiation Oncology (HERO) project. HERO has the overall aim to develop a knowledge base of the provision of radiotherapy in Europe and build a model for health economic evaluation of radiation treatments at the European level. The current access to radiotherapy resources in Europe were recently documented by HERO in collaboration with the European national radiotherapy societies. High income countries especially in Northern-Western Europe are wellserved with radiotherapy resources; other countries are facing important shortages of equipment in general and especially machines capable of delivering high precision conformal treatments (IMRT, IGRT). Despite these variations, the results demonstrated a considerable positive evolution in radiotherapy resources since the ESTRO-QUARTS study in 2005, with higher equipment levels and lower patient loads per unit of equipment or per radiotherapy professional than recommended a decade ago. This evolution has not been the same in all European countries, which to some degree explain the variation seen between countries. Planning for the optimal radiotherapy service on e.g. a national level is a challenge. First of all, detailed estimation of the projected need for radiotherapy, in terms of number of cancer patients requiring radiotherapy now and in the future, is required. This involves merging epidemiological data with evidence-based clinical decision trees. Secondly, solid data on the anticipated throughput (patients per machine, with relevant staff) is needed. Productivity and efficiency is variable from country to country, and is dynamically changing as novel techniques and equipment are introduced. Despite these challenges, early planning is needed as it takes several years from the decision to build or extend a radiotherapy facility is made to the first patient can be treated: equipment must be procured, installed and commissioned, and the staff properly educated. A particularly difficult example is planning for particle radiotherapy, where the indications and future needs are more uncertain, the capital costs higher and the construction times much longer than for conventional radiotherapy. The need for radiotherapy, expressed in terms of the proportion of cancer patients who will have an evidencebased indication for radiotherapy, is not straightforward to assess. The Australian CCORE studies have indicated that about 50% of all cancer patients will at some point in their disease need radiotherapy. In a recent HERO study these estimates have been refined with details about tumor site and stage relevant for each of the European countries. The results indicate that 51% of the 3.4 million new European cancer patients in 2012 were candidates for radiotherapy. A comparison to the actually delivered radiotherapy courses published in the HERO studies revealed that the optimal benchmark is not met in the vast majority of countries, not even the most affluent and well-served countries.
In conclusion, despite improvements in equipment and staffing there is today still a significant underutilization of radiotherapy in most European countries. Combined with the anticipated significant increase in new cancer cases over the next years, this unmet need represents a real challenge to the ESTRO vision for 2020. There is still a long way before every cancer patient in Europe will have access to state-ofthe-art radiotherapy.
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